Related Experiment Video
Updated: May 22, 2026
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype
Aaron B Schultz1,2, Molly Dalzell1,2, Luis Nivelo1,2
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Abstract:
STAT3 signaling is fundamental to T cells, where it underlies basic cellular processes like metabolism and apoptosis, as well as specialized processes like effector differentiation and cytokine production. However, mutations of STAT3 are strikingly prevalent in T-cell cancers, and aberrant or excessive STAT3 signaling is thought to mobilize cellular pathways that encourage malignancy. To better understand how STAT3 mutations drive T-cell cancers, we compared two frequent cancer-associated variants, Y640F and N647I, at the cellular and molecular levels. Using a retrogenic system, we demonstrate that they are qualitatively similar yet quantitatively distinct; each bears a gain-of-function phenotype, but Y640F has greater transcriptome-wide effects. We also discovered that these and other common STAT3 mutants invoke a T regulatory 1 (Tr1) gene program characterized by expression of IL-10 and other factors that dampen T-cell responses, including LAG3 and CD39. Importantly, "Tr1 skewing" is evident in both mouse T cells expressing cancer-associated STAT3 variants and humans afflicted with T-cell malignancies. These studies advance current understanding of how cancer-associated mutations impact STAT3 function and reveal anti-inflammatory properties that may help transformed T cells persist, expand, and/or avoid eradication.
Insights
Mutations in STAT3 (Signal Transducer and Activator of Transcription 3) promote T-cell cancers by activating a Tr1 gene program. This program dampens immune responses, aiding cancer cell survival.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Biology
Background:
- Signal Transducer and Activator of Transcription 3 (STAT3) is crucial for T-cell function, regulating metabolism, apoptosis, and effector differentiation.
- STAT3 mutations are common in T-cell cancers, suggesting a role in malignancy development.
- Aberrant STAT3 signaling can mobilize pathways that promote cancer growth.
Purpose of the Study:
- To compare the cellular and molecular effects of two common cancer-associated STAT3 variants (Y640F and N647I).
- To elucidate the mechanisms by which STAT3 mutations drive T-cell cancers.
- To identify potential therapeutic targets by understanding how STAT3 mutations impact T-cell function.
Main Methods:
- Utilized a retrogenic system in mouse models to study STAT3 variants.
- Performed cellular and molecular-level comparisons of STAT3 Y640F and N647I mutants.
- Analyzed gene expression patterns, including the induction of specific gene programs.
Main Results:
- STAT3 variants Y640F and N647I exhibit gain-of-function phenotypes, with Y640F showing broader transcriptome-wide effects.
- Common STAT3 mutants induce a T regulatory 1 (Tr1) gene program, characterized by IL-10, LAG3, and CD39 expression.
- "Tr1 skewing" was observed in both mouse models and human T-cell malignancies.
Conclusions:
- Cancer-associated STAT3 mutations promote T-cell malignancies through a gain-of-function mechanism.
- The induced Tr1 gene program confers anti-inflammatory properties, potentially aiding cancer cell persistence and immune evasion.
- Understanding STAT3's role in T-cell cancers offers insights into novel therapeutic strategies targeting immune suppression.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
02:23Abnormal Proliferation
02:30Histone Variants at the Centromere
02:23Master Transcription Regulators
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...